메뉴 건너뛰기




Volumn 17, Issue 3, 2010, Pages 480-486

Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study

Author keywords

Ospemifene; Postmenopausal; Selective estrogen receptor modulator; Vulvovaginal atrophy

Indexed keywords

LUBRICATING AGENT; OSPEMIFENE; PLACEBO;

EID: 77952270259     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181c1ac01     Document Type: Article
Times cited : (220)

References (26)
  • 1
    • 0034658676 scopus 로고    scopus 로고
    • Diagnosis and treatment of atrophic vaginitis
    • Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-3096.
    • (2000) Am Fam Physician , vol.61 , pp. 3090-3096
    • Bachmann, G.A.1    Nevadunsky, N.S.2
  • 3
    • 68349155731 scopus 로고    scopus 로고
    • Prevalence and impact of vaginal symptoms among postmenopausal women
    • Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
    • (2009) J Sex Med , vol.6 , pp. 2133-2142
    • Santoro, N.1    Komi, J.2
  • 4
    • 67649365524 scopus 로고    scopus 로고
    • Postmenopausal women's attitudes: Vulvovaginal atrophy and its symptoms [abstract LB-10]
    • Simon JA, Komi J. Postmenopausal women's attitudes: vulvovaginal atrophy and its symptoms [abstract LB-10]. Menopause 2007;14:1107.
    • (2007) Menopause , vol.14 , pp. 1107
    • Simon, J.A.1    Komi, J.2
  • 5
    • 0037125379 scopus 로고    scopus 로고
    • Risk and benefits of estrogen plus progestin in healthy postmenopausal women
    • Writing Group for the Women's Health Initiative Investigators
    • Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
    • (2002) JAMA , vol.288 , pp. 321-333
  • 6
    • 51449124264 scopus 로고    scopus 로고
    • Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society
    • The North American Menopause Society
    • The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
    • (2008) Menopause , vol.15 , pp. 584-602
  • 7
    • 69649108864 scopus 로고    scopus 로고
    • The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society
    • The North American Menopause Society
    • The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-369.
    • Menopause , vol.2007 , Issue.14 , pp. 355-369
  • 9
    • 64049083020 scopus 로고    scopus 로고
    • Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmeno-pausal women
    • Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmeno-pausal women. Menopause 2009;16:30-36.
    • (2009) Menopause , vol.16 , pp. 30-36
    • Labrie, F.1    Cusan, L.2    Gomez, J.L.3
  • 10
    • 37549023420 scopus 로고    scopus 로고
    • Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial
    • Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76.
    • (2008) Obstet Gynecol , vol.111 , pp. 67-76
    • Bachmann, G.1    Lobo, R.A.2    Gut, R.3    Nachtigall, L.4    Notelovitz, M.5
  • 11
    • 58149280795 scopus 로고    scopus 로고
    • Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet
    • Erratum in: Obstet Gynecol 2008;112, 1392
    • Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-1060. Erratum in: Obstet Gynecol 2008;112:1392.
    • (2008) Obstet Gynecol , vol.112 , pp. 1053-1060
    • Simon, J.1    Nachtigall, L.2    Gut, R.3    Lang, E.4    Archer, D.F.5    Utian, W.6
  • 12
    • 64049105055 scopus 로고    scopus 로고
    • Vulvovaginal atrophy: New and upcoming approaches
    • Simon JA. Vulvovaginal atrophy: new and upcoming approaches. Menopause 2009;16:5-7.
    • (2009) Menopause , vol.16 , pp. 5-7
    • Simon, J.A.1
  • 13
    • 17744368482 scopus 로고    scopus 로고
    • Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats
    • Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-820.
    • (2000) Endocrinology , vol.141 , pp. 809-820
    • Qu, Q.1    Zheng, H.2    Dahllund, J.3
  • 14
    • 0034907007 scopus 로고    scopus 로고
    • In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer
    • Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001;77:271-279.
    • (2001) J Steroid Biochem Mol Biol , vol.77 , pp. 271-279
    • Taras, T.L.1    Wurz, G.T.2    Degregorio, M.W.3
  • 15
    • 27744590563 scopus 로고    scopus 로고
    • Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice
    • Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol 2005;97:230-240.
    • (2005) J Steroid Biochem Mol Biol , vol.97 , pp. 230-240
    • Wurz, G.T.1    Read, K.C.2    Marchisano-Karpman, C.3
  • 16
    • 34447637387 scopus 로고    scopus 로고
    • Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ
    • Namba R, Young LJ, Maglione JE, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005;7: 881-889.
    • (2005) Breast Cancer Res , vol.7 , pp. 881-889
    • Namba, R.1    Young, L.J.2    Maglione, J.E.3
  • 17
    • 0642306447 scopus 로고    scopus 로고
    • Effects of ospemifene, a novel SERM, on vascular markers and function in healthy postmeno-pausal women
    • Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy postmeno-pausal women. Menopause 2003;10:440-447.
    • (2003) Menopause , vol.10 , pp. 440-447
    • Ylikorkala, O.1    Cacciatore, B.2    Halonen, K.3
  • 18
    • 0642367765 scopus 로고    scopus 로고
    • Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and on quality of life in postmeno-pausal women: A double-blind randomized trial
    • Rutanen E-M, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and on quality of life in postmeno-pausal women: a double-blind randomized trial. Menopause 2003;10: 433-439.
    • (2003) Menopause , vol.10 , pp. 433-439
    • Rutanen, E.-M.1    Heikkinen, J.2    Halonen, K.3    Komi, J.4    Lammintausta, R.5    Ylikorkala, O.6
  • 20
    • 20144388972 scopus 로고    scopus 로고
    • Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract and tolerability in postmenopausal women
    • Komi J, Lankinen KS, Härkönen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract and tolerability in postmenopausal women. Menopause 2005;12:202-209.
    • (2005) Menopause , vol.12 , pp. 202-209
    • Komi, J.1    Lankinen, K.S.2    Härkönen, P.3
  • 21
    • 33745603721 scopus 로고    scopus 로고
    • Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
    • Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24:314-318.
    • (2006) J Bone Miner Metab , vol.24 , pp. 314-318
    • Komi, J.1    Lankinen, K.S.2    Degregorio, M.3
  • 22
    • 77952253619 scopus 로고    scopus 로고
    • TM (ospemifene) effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study [abstract P2-513]
    • June San Francisco, CA
    • TM (ospemifene), effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study [abstract P2-513]. Paper presented at: Endocrine Society's Annual Meeting; June 15-18, 2008; San Francisco, CA.
    • (2008) Paper Presented At: Endocrine Society's Annual Meeting , pp. 15-18
    • Bachmann, G.A.1    Komi, J.2    Hanley, R.3
  • 23
    • 68349161052 scopus 로고    scopus 로고
    • Ospemifene, a new SERM, improves the symptoms of vaginal dryness and dyspareunia in postmenopausal women: Results from a pivotal phase 3 study [abstract OR6-03]
    • Simon JA, Komi J. Ospemifene, a new SERM, improves the symptoms of vaginal dryness and dyspareunia in postmenopausal women: results from a pivotal phase 3 study [abstract OR6-03]. Climacteric 2008;11:97.
    • (2008) Climacteric , vol.11 , pp. 97
    • Simon, J.A.1    Komi, J.2
  • 24
    • 77952261120 scopus 로고    scopus 로고
    • Ospemifene improves the clinical signs of vaginal atrophy: Results from a pivotal phase 3 study [abstract P48]
    • Portman D, Komi J. Ospemifene improves the clinical signs of vaginal atrophy: results from a pivotal phase 3 study [abstract P48]. Menopause 2008;15:1222.
    • (2008) Menopause , vol.15 , pp. 1222
    • Portman, D.1    Komi, J.2
  • 26
    • 0033649898 scopus 로고    scopus 로고
    • Selective estrogen receptor modulators (SERMs) in clinical practice
    • Plouffe L Jr. Selective estrogen receptor modulators (SERMs) in clinical practice. J Soc Gynecol Investig 2000;7:S38-S46.
    • (2000) J Soc Gynecol Investig , vol.7
    • Plouffe L, Jr.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.